NAUTNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Nautilus Biotechnology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$2.63+0.57 (+27.67%)
Close on Oct 19, 2026
- Market cap
- $334.37M
- P/E (TTM)
- –
- Dividend yield
- –
Nautilus Biotechnology statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Laboratory Analytical Instruments companies for comparison
Valuation
| Measure | Nautilus Biotechnology | Industry median |
|---|---|---|
| Market Cap | $334.68M | $230.55M |
| Enterprise Value | $250.68M | $202.97M |
| PB Ratio | 2.55 | 3.14 |
| P/TBV Ratio | 2.55 | 4.57 |
Income (trailing twelve months)
| Measure | Nautilus Biotechnology | Industry median |
|---|---|---|
| Net Income | -$56.52M | -$6.57M |
| EPS (Diluted) | -$0.45 | -$0.07 |
Returns
| Measure | Nautilus Biotechnology | Industry median |
|---|---|---|
| Return on Equity (ROE) | -36.2% | -19.2% |
| Return on Assets (ROA) | -30.0% | -13.3% |
Balance sheet
| Measure | Nautilus Biotechnology | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $84.00M | $37.33M |
| Net Cash (Debt) | $84.00M | $3.92M |
| Net Cash Per Share | $0.66 | $0.28 |
| Equity (Book Value) | $131.11M | $57.36M |
| Book Value Per Share | $1.03 | $2.81 |
| Tangible Book Value | $131.11M | $10.71M |
| Working Capital | $78.99M | $54.64M |
Financial position
| Measure | Nautilus Biotechnology | Industry median |
|---|---|---|
| Current Ratio | 10.14 | 2.50 |
| Quick Ratio | 9.72 | 1.54 |
Cash flow (trailing twelve months)
| Measure | Nautilus Biotechnology | Industry median |
|---|---|---|
| Operating Cash Flow | -$50.24M | -$653.46K |
| Capital Expenditures | -$1.63M | -$3.69M |
| Free Cash Flow | -$51.86M | -$835.02K |
| FCF Per Share | -$0.41 | -$0.02 |
Efficiency
| Measure | Nautilus Biotechnology | Industry median |
|---|---|---|
| Profits Per Employee | -$434.78K | -$51.88K |
| Employee Count | 130 | 185 |
Dividends and yields
| Measure | Nautilus Biotechnology | Industry median |
|---|---|---|
| Earnings Yield | -16.9% | -6.91% |
| FCF Yield | -15.5% | -0.56% |
Shares
| Measure | Nautilus Biotechnology | Industry median |
|---|---|---|
| Shares Outstanding | 127,255,000 | 44,856,700 |
| Shares Change (YoY) | 0.57% | 3.35% |
| Shares Change (QoQ) | 0.12% | 0.27% |
| Float | 63,022,000 | 37,097,900 |
| Shares Held by Insiders | 50.5% | 10.6% |
| Shares Held by Institutions | 39.4% | 63.5% |
Taxes
| Measure | Nautilus Biotechnology | Industry median |
|---|---|---|
| Income Tax | $0 | $1.52M |
Scores
| Measure | Nautilus Biotechnology | Industry median |
|---|---|---|
| Altman Z-Score | 3.67 | 1.95 |
| Piotroski F-Score | 2 | 5 |
Calculated by StockData from Nautilus Biotechnology's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.